These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23083839)

  • 1. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M; Rogliani P; Ruggeri P; Segreti A; Proietto A; Picciolo S; Matera MG
    Respir Med; 2013 Jun; 107(6):848-53. PubMed ID: 23490225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
    COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y; Kinoshita M; Lee SH; Hang LW; Ichinose M; Fukuchi Y; Kitawaki T; Okino N; Prasad N; Lawrence D; Kramer B
    Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
    Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
    Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD.
    Rogliani P; Ora J; Ciaprini C; Senis L; Stirpe E; Cazzola M
    Respir Med; 2014 Feb; 108(2):307-13. PubMed ID: 24238769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM; Wagner F; Khindri S; Drollmann AF
    COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.